MNKD vs NVO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: NVO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MNKD and NVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MNKD and NVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

MannKind Corporation is a biopharmaceutical company built around its proprietary Technosphere dry-powder inhalation platform and, more recently, endocrine and rare-disease products. Its best-known product is Afrezza, an inhaled mealtime insulin for diabetes, but the larger financial driver has become royalty revenue from Tyvaso DPI, a dry-powder inhaled treatment for pulmonary arterial hypertension and pulmonary fibrosis that United Therapeutics markets under a partnership using MannKind's inhalation technology. MannKind also markets Furoscix, an at-home subcutaneous furosemide therapy for fluid overload associated with conditions like heart failure, which has been ramping quickly. This mix of a growing royalty stream plus its own commercial products distinguishes MannKind from pre-revenue biotechs.

Full MNKD guide

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MNKD drivers: Tyvaso DPI royalties; Furoscix and Afrezza commercial products.
• NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is concentration and dependence on partners and catalysts: a large share of high-margin revenue comes from Tyvaso DPI royalties controlled by United Therapeutics, so any slowdown, competition, or change in that product's trajectory would hit MannKind directly. For NVO, novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MNKD if you believe its drivers more; NVO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MNKD and NVO guides.

MNKD. These figures are approximate and tied to the asOf date; verify live numbers before acting. MannKind is valued as a catalyst-driven biopharma, so its shares hinge on the durability of Tyvaso DPI royalties plus the success of product launches and pipeline readouts rather than a stable earnings multiple. Binary regulatory and clinical events can move the stock sharply, so judge it on catalysts and cash runway as much as current revenue.

NVO. Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.

Headline figures (approximate, Jul 2026): MNKD shows revenue trend Q1 2026 total revenue around $90 million, up roughly 15% year over year, revenue drivers Tyvaso DPI royalties (~$33M), Afrezza (~$15M), and Furoscix (~$15.5M) in Q1 2026, profitability Reported a net loss in Q1 2026 while investing in growth; profitability is not yet consistent, ambition Management has pointed to a roughly $450 million revenue run-rate goal supported by launches and catalysts; NVO shows revenue (ttm) ~$40 billion (approximate, verify; reported in Danish kroner), operating margin ~45% (approximate, verify), net margin ~35% (approximate, verify), glp-1 share of revenue Majority of sales from semaglutide products (approximate).

MNKD and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MNKD and NVO exposure against your real portfolio. It is not an investment adviser.